Galapagos NV ADR (GLPG) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Galapagos NV ADR (GLPG) has a cash flow conversion efficiency ratio of -0.025x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-82.75 Million) by net assets ($3.25 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Galapagos NV ADR to measure how much of total assets are equity-financed.
Galapagos NV ADR - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how Galapagos NV ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Galapagos NV ADR (GLPG) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Galapagos NV ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Galapagos NV ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chang Wah Technology Co Ltd
TWO:6548
|
0.038x |
|
ChengDu Hi-Tech Development Co Ltd
SHE:000628
|
0.041x |
|
PG Electroplast Limited
NSE:PGEL
|
-0.053x |
|
Befar Group Co Ltd
SHG:601678
|
0.014x |
|
Sichuan Tuopai Shede Wine Co Ltd
SHG:600702
|
-0.038x |
|
Beijing Originwater Technology
SHE:300070
|
-0.006x |
|
Opple Lighting Co Ltd
SHG:603515
|
1.058x |
|
Shenzhen Hopewind Elec Co Ltd
SHG:603063
|
0.038x |
Annual Cash Flow Conversion Efficiency for Galapagos NV ADR (2004–2025)
The table below shows the annual cash flow conversion efficiency of Galapagos NV ADR from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see GLPG market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $3.23 Billion | $-189.23 Million | -0.059x | +47.04% |
| 2024-12-31 | $2.90 Billion | $-320.03 Million | -0.110x | +23.93% |
| 2023-12-31 | $2.80 Billion | $-405.97 Million | -0.145x | +26.71% |
| 2022-12-31 | $2.53 Billion | $-500.54 Million | -0.198x | -3.96% |
| 2021-12-31 | $2.64 Billion | $-503.83 Million | -0.191x | -19.10% |
| 2020-12-31 | $2.67 Billion | $-427.34 Million | -0.160x | -112.79% |
| 2019-12-31 | $2.88 Billion | $3.60 Billion | 1.251x | +1166.08% |
| 2018-12-31 | $1.21 Billion | $-142.47 Million | -0.117x | +19.24% |
| 2017-12-31 | $1.01 Billion | $-147.03 Million | -0.145x | -146.04% |
| 2016-12-31 | $758.70 Million | $239.40 Million | 0.316x | +200.51% |
| 2015-12-31 | $365.00 Million | $-114.59 Million | -0.314x | +14.35% |
| 2014-12-31 | $206.13 Million | $-75.56 Million | -0.367x | -11835.82% |
| 2013-12-31 | $167.14 Million | $522.00K | 0.003x | -99.42% |
| 2012-12-31 | $118.45 Million | $64.10 Million | 0.541x | +634.28% |
| 2011-12-31 | $118.38 Million | $-11.99 Million | -0.101x | +19.01% |
| 2010-12-31 | $148.51 Million | $-18.57 Million | -0.125x | -316.03% |
| 2009-12-31 | $108.88 Million | $6.30 Million | 0.058x | +159.47% |
| 2008-12-31 | $84.32 Million | $-8.21 Million | -0.097x | -2687.95% |
| 2007-12-31 | $98.63 Million | $371.00K | 0.004x | +104.43% |
| 2006-12-31 | $109.54 Million | $-9.31 Million | -0.085x | -33.68% |
| 2005-12-31 | $61.14 Million | $-3.89 Million | -0.064x | +75.68% |
| 2004-12-31 | $10.37 Million | $-2.71 Million | -0.261x | -- |
About Galapagos NV ADR
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product c… Read more